Baseline patient characteristics
| . | All patients . | DSA . | ||||
|---|---|---|---|---|---|---|
| No . | Single . | Double . | Any . | P* . | ||
| Sample size | 73 | 55 | 11 | 7 | 18 | |
| Median age, y (range) | 48 (19-67) | 48 (21-67) | 48 (19-63) | 55 (33-64) | 48 (19-64) | .89 |
| Male (%) | 39 (53.4) | 31 (56.4) | 7 (63.6) | 1 (14.3) | 8 (44.4) | .38 |
| Prior transplant (%) | 18 (24.7) | 16 (29.1) | 2 (18.2) | 0 (0) | 2 (11.1) | .21 |
| Diagnosis | .14 | |||||
| NHL/CLL/HD (%) | 29 (39.7) | 24 (43.6) | 3 (27.3) | 2 (28.6) | 5 (27.7) | |
| AML (%) | 22 (30.1) | 18 (32.7) | 2 (18.2) | 2 (28.6) | 4 (22.2) | |
| MDS/MPD (%) | 9 (12.3) | 6 (10.9) | 2 (18.2) | 1 (14.3) | 3 (16.6) | |
| ALL (%) | 5 (6.9) | 3 (5.5) | 2 (18.2) | 0 (0) | 2 (11.1) | |
| SAA (%) | 5 (6.9) | 2 (3.6) | 1 (9.1) | 2 (28.6) | 3 (16.7) | |
| CML (%) | 3 (4.1) | 2 (3.6) | 1 (9.1) | 0 (0) | 1 (5.6) | |
| RIC conditioning (%) | 53 (72.6) | 40 (72.7) | 7 (63.6) | 6 (85.7) | 13 (72.2) | 1 |
| Tac/Sir GVHD prophylaxis (%) | 49 (67.1) | 35 (63.6) | 8 (72.70) | 6 (85.7) | 14 (77.8) | .48 |
| 4/6 + 4/6 HLA match (%) | 54 (74.0) | 41 (74.5) | 9 (81.8) | 4 (57.1) | 13 (72.2) | 1 |
| Median follow-up, mo | 33.8 | 30.3 | 30.3 | N/A | 30.3 | .92 |
| . | All patients . | DSA . | ||||
|---|---|---|---|---|---|---|
| No . | Single . | Double . | Any . | P* . | ||
| Sample size | 73 | 55 | 11 | 7 | 18 | |
| Median age, y (range) | 48 (19-67) | 48 (21-67) | 48 (19-63) | 55 (33-64) | 48 (19-64) | .89 |
| Male (%) | 39 (53.4) | 31 (56.4) | 7 (63.6) | 1 (14.3) | 8 (44.4) | .38 |
| Prior transplant (%) | 18 (24.7) | 16 (29.1) | 2 (18.2) | 0 (0) | 2 (11.1) | .21 |
| Diagnosis | .14 | |||||
| NHL/CLL/HD (%) | 29 (39.7) | 24 (43.6) | 3 (27.3) | 2 (28.6) | 5 (27.7) | |
| AML (%) | 22 (30.1) | 18 (32.7) | 2 (18.2) | 2 (28.6) | 4 (22.2) | |
| MDS/MPD (%) | 9 (12.3) | 6 (10.9) | 2 (18.2) | 1 (14.3) | 3 (16.6) | |
| ALL (%) | 5 (6.9) | 3 (5.5) | 2 (18.2) | 0 (0) | 2 (11.1) | |
| SAA (%) | 5 (6.9) | 2 (3.6) | 1 (9.1) | 2 (28.6) | 3 (16.7) | |
| CML (%) | 3 (4.1) | 2 (3.6) | 1 (9.1) | 0 (0) | 1 (5.6) | |
| RIC conditioning (%) | 53 (72.6) | 40 (72.7) | 7 (63.6) | 6 (85.7) | 13 (72.2) | 1 |
| Tac/Sir GVHD prophylaxis (%) | 49 (67.1) | 35 (63.6) | 8 (72.70) | 6 (85.7) | 14 (77.8) | .48 |
| 4/6 + 4/6 HLA match (%) | 54 (74.0) | 41 (74.5) | 9 (81.8) | 4 (57.1) | 13 (72.2) | 1 |
| Median follow-up, mo | 33.8 | 30.3 | 30.3 | N/A | 30.3 | .92 |
NHL/CLL/HD indicates non-Hodgkin lymphoma/chronic lymphocytic leukemia/Hodgkin disease; AML, acute myelogenous leukemia; MDS/MPD, myelodysplastic syndrome/myeloproliferative disease; ALL, acute lymphoblastic leukemia; SAA, severe aplastic anemia; CML, chronic myelogenous leukemia; RIC, reduced intensity conditioning; Tac/Sir, tacrolimus/sirolimus; and N/A, not applicable.
P values represent the comparison between no DSA versus any DSA.